Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | FASN | P49327 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140359 | 0.95 | DDR2 (0.53) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL1140453 | 0.91 | DDR2 (0.49) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL6364860 | 0.90 | DDR2 (0.49) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL1140747 | 0.90 | MAPK14 (0.51) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL1140736 | 0.90 | PANK3 (0.50) | PANK3DDR2FASNPPARGABL1 | |
| SCHEMBL6341049 | 0.89 | DDR2 (0.48) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL1140394 | 0.88 | GPR6 (0.47) | DDR2FASNPPARGABL1CXCR3 | |
| SCHEMBL1140297 | 0.88 | FASN (0.49) | DDR2FASNPPARGABL1MAPK14 | |
| SCHEMBL6343772 | 0.88 | DDR2 (0.49) | PANK3DDR2ABL1LCKCSF1R | |
| SCHEMBL1229935 | 0.88 | MAPK14 (0.50) | DDR2FASNPPARGMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | claimed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | disclosed |
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| EP-2346499-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011062939-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110039850-A1 | Leukemia Treatment | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2011-02-17 | — | — | US | disclosed |
| WO-2011019798-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183962-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | PANK3 869/4885DDR2 1123/4885FASN 628/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | PANK3 4134/4885DDR2 1167/4885FASN 3081/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | PANK3 2624/4885DDR2 704/4885FASN 2368/4885 |
| US-20110039850-A1 | Leukemia Treatment | ABL1, MCL1, BCR | PANK3 3550/4885DDR2 633/4885FASN 4435/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | PANK3 2624/4885DDR2 704/4885FASN 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.